Show simple item record

dc.contributor.authorSwitzer, B
dc.contributor.authorHaanen, J
dc.contributor.authorLorigan, PC
dc.contributor.authorPuzanov, I
dc.contributor.authorTurajlic, S
dc.date.accessioned2021-09-22T14:27:20Z
dc.date.available2021-09-22T14:27:20Z
dc.identifier.citationJournal for immunotherapy of cancer, 2021, 9 (7)
dc.identifier.issn2051-1426
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4824
dc.identifier.eissn2051-1426
dc.identifier.doi10.1136/jitc-2021-002835
dc.description.abstractThe clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regarding the use of immune checkpoint inhibitors (ICIs) in patients with cancer during the SARS-CoV-2 pandemic, with a focus on patients with melanoma and renal cell carcinoma (RCC). More specifically, we summarize the theoretical concepts and available objective data regarding the relationships between ICIs and the antiviral immune response, along with recommended clinical approaches to the management of melanoma and RCC patient cohorts receiving ICIs throughout the course of the COVID-19 pandemic. Additional insights regarding the use of ICIs in the setting of current and upcoming COVID-19 vaccines and broader implications toward future pandemics are also discussed.
dc.formatPrint
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectMelanoma
dc.subjectCarcinoma, Renal Cell
dc.subjectKidney Neoplasms
dc.subjectImmunotherapy
dc.subjectPandemics
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectCOVID-19 Vaccines
dc.subjectImmune Checkpoint Inhibitors
dc.titleClinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors.
dc.typeJournal Article
dcterms.dateAccepted2021-06-21
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1136/jitc-2021-002835
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal for immunotherapy of cancer
pubs.issue7
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.publication-statusPublished
pubs.volume9
pubs.embargo.termsNot known
dc.contributor.icrauthorTurajlic, Samraen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0